血小板生成素受体激动剂治疗血小板减少症:ITP及 beyond
本文报告了单中心最大规模艾曲泊帕治疗经验,共62例患者。严重ITP患者(n=34)应答率91.2%,中位持续18.5个月;桥接治疗组(n=15)完全应答率93.3%;非ITP组(n=13)应答率76.9%。副作用短暂,2例因轻微并发症停药。作者认为艾曲泊帕治疗严重ITP有效且耐受良好,并可能用于非ITP相关血小板减少,值得进一步研究。
要点
- 严重ITP患者(n=34)艾曲泊帕应答率91.2%,中位持续18.5个月,41.4%(n=14)达完全应答。
- 桥接手术组(n=15)完全应答率93.3%,非ITP组(n=13)应答率76.9%。
- 副作用短暂,仅2例因轻微并发症(皮疹、恶心、腹泻)停药。
核心结论
- 艾曲泊帕治疗严重ITP有效且耐受良好。
- 对通常不需治疗但术前需暂时提升血小板的ITP患者有益。
- 在ITP之外对抗血小板减少可能有更广泛意义,值得进一步研究。
研究设计与样本
- 单中心经验,共62例患者接受艾曲泊帕治疗。
- 严重ITP组34例,桥接手术组15例(基线血小板较高),非ITP组13例。
主要发现
- 严重ITP组(n=34)应答率91.2%,中位持续18.5个月。
- ITP病例中41.4%(n=14)达完全应答(血小板>100×10^9/L),2例停药后维持完全应答。
- 桥接组(n=15)完全应答率93.3%。
- 非ITP组(n=13)应答率76.9%。
- 所有组副作用均为短暂性,2例因轻微并发症(皮疹、恶心、腹泻)停药。
关键数值与推荐
- 完全应答定义为血小板计数>100×10^9/L。
临床怎么用
- 艾曲泊帕可用于严重ITP的治疗。
- 对通常不需治疗但术前需暂时提升血小板的ITP患者,艾曲泊帕具有优势。
- 非ITP相关血小板减少的使用潜力值得进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Eltrombopag is well established in treatment of severe immune thrombocytopenia (ITP) and is increasingly commonplace in second-line management. A role is also suggested for both bridging therapy for surgery, as well as treating thrombocytopenia due to non-immune aetiologies. We present the largest single-centre experience with eltrombopag, with our cohort of 62 patients. Patients with severe ITP (n = 34) had 91·2% response, which was sustained over a median of 18·5 months. In 41·4% of ITP cases (n = 14), complete response (CR- platelet count >100 × 109 /l) was achieved and in 2 cases, therapy was stopped and CR maintained. In our bridging group (n = 15) with a higher baseline platelet count, 93·3% achieved a CR. In the non-ITP group (n = 13), a response was achieved in 76·9%. In all groups, side effects were transient, with the drug discontinued in 2 patients due to minor complications (rash, nausea, diarrhoea). We conclude that eltrombopag is both effective and well tolerated as therapy in severe ITP. It is also advantageous in ITP patients who do not normally require therapy, but need a temporary platelet count boost pre-procedure. Furthermore, there are potentially far wider implications for the use of eltrombopag in counteracting thrombocytopenia beyond ITP, which merit further investigation.
引用
- Taylor A, Westwood JP, Laskou F, et al. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond. Br J Haematol. 2017. PMID: 28295201. doi:10.1111/bjh.14564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。